The American Academy of Pediatrics has reaffirmed its autism treatment guidelines, ignoring legal warnings and recent bans on aversive methods, raising concerns over inconsistent standards and clinical guidance.
The American Academy of Pediatrics has placed itself in an awkward position. In October 2025, the organisation reaffirmed its autism clinical report from 2020 without changing its language, even though its own legal team had already told a federal court that aversive practices used at the Judge Rotenberg Centre were dangerous and ethically indefensible. The result is a public mismatch between the academy’s scientific guidance and its legal stance.
That legal position mattered. In a 2023 amicus brief, the academy’s lawyers condemned contingent electric shock as punishment for autistic people and argued that it lacked scientific support and violated paediatric ethics. The Food and Drug Administration had already taken a similar view in 2020, when it banned the devices after years of concern about their safety and use. According to reporting on the FDA’s action and the later court challenge, the ban was later overturned on technical grounds rather than because the agency had changed its view of the underlying evidence.
Yet the reaffirmed guideline did not mention any of that. It continued to support applied behaviour analysis, or ABA, as a first-line treatment without addressing the therapy’s historical links to aversive methods or the academy’s own legal warning about the most extreme form of punishment-based treatment. Critics say that omission is more than a paperwork problem: if one branch of the organisation publicly rejects a practice while another leaves the existing guidance untouched, clinicians and policy-makers are left with mixed signals.
That matters because professional guidelines shape insurance coverage, training, clinical norms and state policy. The article argues that reaffirmation is not a neutral act when evidence, ethics and an organisation’s own public statements have moved on. In that view, the academy’s silence on its legal brief and on the FDA’s ban amounts to an institutional failure of review, not simply an editorial oversight.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
